C D BROOKS
Overview
Explore the profile of C D BROOKS including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
BROOKS C
J Rheumatol
. 2001 May;
28(4):845-53.
PMID: 11327261
Objective: Sulfasalazine (SSZ) has regulatory approval for treatment of inflammatory bowel disease in children and adults, and for use as a slow acting agent in adult rheumatoid arthritis (RA). This...
3.
Kolasa T, Gunn D, Bhatia P, Basha A, Craig R, Stewart A, et al.
J Med Chem
. 2000 Sep;
43(17):3322-34.
PMID: 10966751
Symmetrical bis(quinolylmethoxyphenyl)alkylcarboxylic acids were investigated as inhibitors of leukotriene biosynthesis and 4, 4-bis(4-(2-quinolylmethoxy)phenyl)pentanoic acid sodium salt (47.Na) met our design parameters for a drug candidate (ABT-080). This compound was readily...
4.
Kolasa T, Gunn D, Bhatia P, Woods K, Gane T, Stewart A, et al.
J Med Chem
. 2000 Feb;
43(4):690-705.
PMID: 10691695
A novel series of heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids was studied as leukotriene biosynthesis inhibitors. A hypothesis of structure-activity optimization by insertion of an oxime moiety was investigated using REV-5901 as a starting...
5.
Bouska J, Bell R, Goodfellow C, Stewart A, BROOKS C, Carter G
Drug Metab Dispos
. 1997 Oct;
25(9):1032-8.
PMID: 9311617
An in vitro glucuronidation assay was used to optimize a series of N-hydroxyurea-containing 5-lipoxygenase inhibitors for metabolic stability. The glucuronidation of these compounds in cynomolgus monkey microsomes followed Michaelis-Menten kinetics...
6.
Stewart A, Bhatia P, Martin J, Summers J, Rodriques K, Martin M, et al.
J Med Chem
. 1997 Jun;
40(13):1955-68.
PMID: 9207936
The discovery of second generation N-hydroxyurea 5-lipoxygenase inhibitors was accomplished through the development of a broad structure-activity relationship (SAR) study. This study identified requirements for improving potency and also extending...
7.
Daley-Yates P, Gregory A, BROOKS C
Br J Clin Pharmacol
. 1997 Jun;
43(6):593-601.
PMID: 9205819
Aims: The aim of this study was to establish whether pharmacokinetic differences between two pro-drugs of methylprednisolone (MP) are likely to be of clinical significance. Methods: This study was a...
8.
BROOKS C, Chene B, Klott K, Busboom S, Francom S
Am J Rhinol
. 1997 Mar;
11(2):117-22.
PMID: 9129753
This study examined the effects of low dose systemic corticoid (methylprednisolone, MP), standard dose antihistamine (terfenadine, TF) or the combination on response to out-of-season acute allergen challenge. We feel that...
9.
Kolasa T, Bhatia P, BROOKS C, Hulkower K, Bouska J, HARRIS R, et al.
Bioorg Med Chem
. 1997 Mar;
5(3):507-14.
PMID: 9113329
A series of substituted indolylalkoxyiminoalkylcarboxylates were found to be potent leukotriene biosynthesis inhibitors. The structure-activity relationships were investigated. Representative potent inhibitors identified were the quinolyl 3a (A-86885) and pyridyl 3b...
10.
Bell R, HARRIS R, Malo P, Bouska J, Shaughnessy T, Hulkower K, et al.
J Pharmacol Exp Ther
. 1997 Mar;
280(3):1366-73.
PMID: 9067325
Our primary goal has been to discover leukotriene biosynthesis inhibitors with characteristics that are appropriate for use as clinical agents. The success of the use of zileuton in the treatment...